Cited by 637Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

The DOI matches its Crossref record.

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Open access

Chesi, Marta, Nardini, Elena, Brents, Leslie A., Schröck, Evelin, Ried, Thomas, Kuehl, W. Michael, Bergsagel, P. Leif·1997·Nature Genetics

DOI 10.1038/ng0797-260PMC PMC3901950

Open this paper in CoChat — free account

Abstract

Dysregulation of oncogenes by translocation to the IgH locus (14q32) is a seminal event in the pathogenesis of B-cell tumours. In multiple myeloma (MM), translocations to the IgH locus have been reported at an incidence of 20-60%. For most translocations, the partner chromosome is unknown (14q+); for the others, a diverse array of chromosomal partners have been identified, with 11q13 (cyclin D1) the only chromosome that is frequently involved. Recently, we developed a Southern-blot assay that detects translocation breakpoint fragments in most MM tumours, including those with no translocation detected by conventional karyotyping. In a continuing analysis of translocation in 21 myeloma cell lines and primary tumours, we show that the novel, karyotypically silent translocation t(4;14)(p16.3;q32.3) is present in five lines and at least three of ten primary tumours. The chromosome-4 breakpoints are clustered in a 70-kb region centromeric to the fibroblast growth factor receptor 3 gene (FGFR3), the apparent dysregulated oncogene. Two lines and one primary tumour with this translocation selectively express an FGFR3 allele containing activating mutations identified previously in thanatophoric dwarfism. We propose that after the t(4;14) translocation, somatic mutation during tumour progression frequently generates in FGFR3 protein that is active in the absence of ligand.

Integrity signals

Registry

Crossref · 10.1038/ng0797-260

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No references could be resolved yet.

Research works printed but not linked: 31

Korsmeyer, S.J. Chromosomal translations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol. 10, 785–607 (1992). · DOI
Taniwaki, M. et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84, 2283–2290 (1994). · DOI
Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 82, 41–49 (1995). · DOI
Lai, J.L. et al. Improved cytogenetics in multiple-myeloma—a study of 151 patients including 117 patients at diagnosis. Blood 85, 2490–2497 (1995). · DOI
Chesi, M. et al. Dysregulation of Cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674–681 (1996). · DOI
Bergsagel, P.L. et al. Promiscuous translations into IgH switch regions in multiple myeloma. Proc. Natl. Sci. Acad. USA 93, 13931–13936 (1996). · DOI · Paper page
Baxendale, S. et al. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nature Genet. 4, 181–186 (1993). · DOI
Keegan, K., Johnson, D., William, L.T. & Hayman, M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad Sci. USA 88, 1095–1099(1991). · DOI
Keegan, K., Meyer, S. & Hayman, M.J. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6, 2229–2236 (1991).
Muenke, M. & Schell, U. Fibroblast-growth-factor-receptor mutations in human sketetal disorders. Trends Genet. 11, 308–313 (1995). · DOI
Naski, M.C., Wang, Q., Xu, J. & Ornitz, D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet. 13, 233–237 (1996). · DOI
Webster, M.K., D'Avis, P.Y., Robertson, S.C. & Donoghue, D.J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16, 4081–4087 (1996). · DOI
Webster, M.K. & Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520–527 (1996). · DOI
Rousseau, F. et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism typeI (TD1). Hum. Mol. Genet. 5, 509–512 (1996). · DOI
Francomano, C.A. et al. A new skeletal dysplasia with severe tibial bowing, profound developmental delay and acanthosis nigricans is caused by a Lys 650 Met mutation in fibroblast growth factor receptor 3 (FGFR3). Am. J. Hum. Genet. 59, A25 (1996).
Tavormina, P.L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 9, 321–328 (1995). · DOI
Williams, M.E., Swerdlow, S.H. & Meeker, T.C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7, 1437–1440 (1993).
Tsujimoto, Y. et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315, 340–343 (1985). · DOI
de Boer, C.J. et al. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 53, 4148–4152 (1993).
Mason, I.J. The ins and outs of fibroblast growth factors. Cell 78, 547–552 (1994). · DOI
Su, W.S. et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288–292 (1997). · DOI
Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390–397 (1996). · DOI
Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911–921 (1996). · DOI
Ornitz, D.M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267, 16305–16311 (1992). · DOI
Caligaris-Cappio, F. et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77, 2688–2693 (1991). · DOI
Allouche, M. Basic fibroblast growth factor and hematopoiesis. Leukemia 9, 937–942 (1995).
Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335–342 (1994). · DOI
Johnston, C.L., Cox, H.C., Gomm, J.J. & Coombes, R.C. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. J. Biol. Chem. 270, 30643–30650 (1995). · DOI
Schröck, E. et al. Multicolor spectral karyotyping of human chromosomes. Science 273, 494–497 (1996). · DOI
Kuehl, W.M., Brents, L.A., Chesi, M. & Bergsagel, P.L. Selective expression of one c-myc allele in two human myeloma cell lines. Cancer Res. 56, 4370–4373 (1996).
Davis, L.G., Kuehl, W.M. & Battey, J.F., Methods in Molecular Biology (Appleton & Lange, Norwalk, Connecticut, 1994).

Sorted by citations

Fibroblast growth factor signalling: from development to cancer
Turner, N. C., & Grose, R. P. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2780 · Cited by 2,768
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 978
Mechanisms of B-cell lymphoma pathogenesis
Küppers, R. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1589 · Cited by 966
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 940
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J. W., Shaughnessy, J. D., Gutierrez, N. C., Stewart, A. K., Morgan, G. J., Ness, B. V., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citation
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Self-citation
Cellular Origin of Human B-Cell Lymphomas
Küppers, R., Klein, U., Hansmann, M., & Rajewsky, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412007 · Cited by 715
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., de Oliveira, C. C. B., Ricol, D., de Medina, S. D., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 743
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1745 · Cited by 688
Mechanisms of chromosomal translocations in B cell lymphomas
Küppers, R., & Dalla‐Favera, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204640 · Cited by 680
“…1996), lyt-10 [t(10;14)] in di use large cell lymphoma (Neri et al., 1991), MUC1 [t(1;14)] in an extranodal lymphoma (Gilles et al., 2000), and ®broblast growth factor receptor 3 [t(4;14)], c-maf [t(14;16)] and MUM1/IRF4 [t(6;14)] in multiple myeloma (Chesi et al., 1997, 1998a; Iida et al., 1997).”
Background
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 583
Self-citation
Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel, P., & Kuehl, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 554
Self-citation
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 543
Genetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J. W., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 685
Self-citation
Chromosome translocations in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204641 · Cited by 478
“…of conventional cytogenetics, SKY analyses, metaphase FISH analyses, isolation of molecular clones, and RT±PCR assays (Bergsagel et al., 1996; Chesi et al., 1997, 1998a; Gabrea et al., 1999; Shaughnessy et al., 2001; Shou et al., 2000; Kuehl, 2001, unpublished results), we have identi®ed at…”
BackgroundSelf-citation
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Gavine, P. R., Mooney, L. M., Kilgour, E., Thomas, A. P., Al-Kadhimi, K. J., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 507
Oncogene addiction: setting the stage for molecularly targeted cancer therapyPreprint
Sharma, S. V., & Settleman, J. E. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 451
“3) (Chesi et al. 1997).”
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Douget, M. L., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., SCHMID, H. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 485
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080161 · Cited by 392
“Somatic mutations in the FGFR-3, similar to the activating mutations in skeletal dysplasias, have been identiﬁed in bladder cancer and in multiple myeloma (Chesi et al. 1997, Capellen et al. 1999).”
Background
Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma
Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T., & Kuehl, W. M. (1998) · Blood · doi:10.1182/blood.v91.12.4457 · Cited by 400
Self-citation
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats, J., Reiman, T., Maxwell, C., Taylor, B. J., Larratt, L., Mant, M., Belch, A., & Pilarski, L. (2003) · Blood · doi:10.1182/blood-2002-06-1675 · Cited by 395
Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
Rubin, B. P., Chen, C.-J., Morgan, T., Sheng, X., Grier, H., Kozakewich, H., Perez-Atayde, A., & Fletcher, J. (1998) · American Journal of Pathology · doi:10.1016/s0002-9440(10)65732-x · Cited by 394
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Dieci, M. V., Arnedos, M., André, F., & Soria, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0362 · Cited by 417
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Egan, J. B., Shi, C.-X., Tembe, W., Christoforides, A., Kurdoglu, A. A., Sinari, S. A., Middha, S., Asmann, Y. W., Schmidt, J. E., Braggio, E., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405977 · Cited by 413
Self-citation
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Dutt, A., Ramos, A. H., Hammerman, P. S., Mermel, C. H., Cho, J., Sharifnia, T., Chande, A. G., Tanaka, K., Stransky, N., Greulich, H. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020351 · Cited by 374
“have been identified in multiple myeloma and bladder cancer”
Background
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.
Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M., Harousseau, J., Minvielle, S., & Bataille, R. (2002) · Blood · doi:10.1182/blood.v99.6.2185 · Cited by 356
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.
Shou, Y., Martelli, M., Gabrea, A., Qi, Y., Brents, L., Roschke, A., Dewald, G., Kirsch, I., Bergsagel, P., & Kuehl, W. (2000) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.97.1.228 · Cited by 356
Self-citation
Genomic abnormalities in monoclonal gammopathy of undetermined significance
Fonseca, R., Bailey, R. J., Ahmann, G. J., Rajkumar, S. V., Hoyer, J. D., Lust, J. A., Kyle, R. A., Gertz, M. A., Greipp, P. R., & Dewald, G. W. (2002) · Blood · doi:10.1182/blood.v100.4.1417.h81602001417_1417_1424 · Cited by 348
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025.421k53_3025_3034 · Cited by 343
Self-citation
WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma.
Stec, I., Wright, T. J., van Ommen, G. V., de Boer, P. D., van Haeringen, A., Moorman, A., Altherr, M., & Dunnen, J. D. D. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1071 · Cited by 341
The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies
Willis, T. G., & Dyer, M. J. S. (2000) · Blood · doi:10.1182/blood.v96.3.808.015k30_808_822 · Cited by 324
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
Fonseca, R., Blood, E., Oken, M. M., Kyle, R. A., Dewald, G. W., Bailey, R. J., Wier, S. A. V., Henderson, K. J., Hoyer, J. D., Harrington, D. P., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3735 · Cited by 336
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn, B. V., Vis, A. N., van der Kwast, T., Kirkels, W., Radvanyi, F., Ooms, E. C., Chopin, D., Boevé, E., Jöbsis, A. C., & Zwarthoff, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.073 · Cited by 331
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 345
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Krook, M. A., Reeser, J. W., Ernst, G., Barker, H. D., Wilberding, M., Li, G., Chen, H., & Roychowdhury, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01157-0 · Cited by 383
Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
Haugsten, E. M., Więdłocha, A., Olsnes, S., & Wesche, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0168 · Cited by 320
“About 15% to 20% of MM patients harbor a chromosomal translocation, t(4;14), which brings FGFR3 under the influence of a strong IgH enhancer region, leading to FGFR3 overexpression (34, 56, 57).”
Background
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
Trudel, S., Li, Z., Wei, E. N., Wiesmann, M., Chang, H., Chen, C. I., Reece, D. E., Heise, C. C., & Stewart, A. K. (2004) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 292
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., & Mohammadi, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.028 · Cited by 300
“…to K659 of FGFR2, also should lead to receptor hyperactivation in human skeletal disorders (Bellus et al., 2000) and cancer (Cappellen et al., 1999; Chesi et al., 1997; Pollock et al., 2007; Richelda et al., 1997) by driving the A loop to an active conformation and indirectly disengaging the brake…”
BackgroundInfluential
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J., & Donoghue, D. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 287
“Glu) of FGFR3 has been shown to underlie the lethal development disorder thanatophoric dysplasia type II (TDII) (Tavormina et al., 1995), and has also been detected in several human malignancies (Cappellen et al., 1999; Chesi et al., 1997; Richelda et al., 1997).”
Background
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N. A., Kalyan, A., Matsangou, M., Costa, R. L. B., Carneiro, B. A., Villaflor, V. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 303
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M. J., Bergsagel, P. L., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 750
Self-citation
A gene expression signature for high-risk multiple myeloma
Kuiper, R., Broyl, A., de Knegt, Y., van Vliet, M. H., van Beers, E. H., van der Holt, B., el Jarari, L., Mulligan, G., Gregory, W. M., Morgan, G. J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.127 · Cited by 296
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
Desnoyers, L. R., Pai, R., Ferrando, R., Hotzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 266
The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts
Chesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 569
Self-citation
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S. A., Stawicki, S. S., Tien, J., Tótpál, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 253
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 255
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Ledergor, G., Weiner, A., Zada, M., Wang, S.-Y., Cohen, Y. C., Gatt, M. E., Snir, N., Magen, H., Koren-Michowitz, M., Herzog-Tzarfati, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0269-2 · Cited by 263
Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies
Li, E., & Hristova, K. A. (2006) · Biochemistry · doi:10.1021/bi060609y · Cited by 266
Mechanism of FGF receptor dimerization and activation
Sarabipour, S., & Hristova, K. (2016) · Nature Communications · doi:10.1038/ncomms10262 · Cited by 245
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Self-citation
Survival and Proliferation Factors of Normal and Malignant Plasma Cells
Klein, B., Tarte, K., Jourdan, M., Mathouk, K., Moreaux, J., Jourdan, É., Legouffe, É., Vos, J. D., & Rossic, J. F. (2003) · International Journal of Hematology · doi:10.1007/bf02983377 · Cited by 217
Achondroplasia: Development, pathogenesis, and therapy
Ornitz, D. M., & Legeai‐Mallet, L. (2016) · Developmental Dynamics · doi:10.1002/dvdy.24479 · Cited by 279
“…oncological field, which is not surprising because the genetic lesions leading to FGFR3-related skeletal disorders are identical to those found in FGFR3-driven cancers (e.g., bladder tumors, multiple myeloma) (Chesi et al., 1997; Cappellen et al., 1999; Turner and Grose, 2010; Patani et al., 2016).”
Background
The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.
Popovici, C., Zhang, B., Grégoire, M., Jonveaux, P., Lafage-Pochitaloff, M., Birnbaum, D., & Pébusque, M. (1999) · Blood · doi:10.1182/blood.v93.4.1381.404k30_1381_1389 · Cited by 226
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T., Lombardi, L., Maiolo, A., et al. (1997) · Blood · doi:10.1182/blood.v90.10.4062 · Cited by 219
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.
Hafner, C., van Oers, J. V., Vogt, T., Landthaler, M., Stoehr, R., Blaszyk, H., Hofstaedter, F., Zwarthoff, E., & Hartmann, A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28163 · Cited by 217
“Somatic activating FGFR3 mutations have been identified in 40% of human seborrheic keratoses (26) and in several human cancers (4), including multiple myeloma (27), urothelial carcinoma (28), cervix carcinoma (29), and colorectal carcinoma (30).”
A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos.
Iwata, T., Chen, L., Li, C.-L., Ovchinnikov, D., Behringer, R., Francomano, C., & Deng, C.-X. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.11.1603 · Cited by 217
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
French, D., Lin, B. C., Wang, M.-T., Adams, C. W., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216
Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias
Foldynova-Trantirkova, S., Wilcox, W. R., & Krejci, P. (2012) · Human Mutation · doi:10.1002/humu.21636 · Cited by 216
“…nevi (MIM# 162900), seborrheic keratosis (MIM# 182000), and acanthosis nigricans, as well as various types of cancer (multiple myeloma [MM], bladder and cervical carcinoma, seminoma) [Cappellen et al., 1999; Chesi et al., 1997; Goriely et al., 2009; Hafner et al., 2006; Logie et al., 2005].”
Background
Cell responses to FGFR3 signalling: growth, differentiation and apoptosis
L’Hôte, C., & Knowles, M. A. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.11.012 · Cited by 218
Genetic events in the pathogenesis of multiple myeloma
Chng, W. J., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.004 · Cited by 189
Self-citation
Epithelial Cell Plasticity in Development and Tumor Progression
Thiery, J., & Chopin, D. (2004) · Cancer Metastasis Review · doi:10.1023/a:1006256219004 · Cited by 209
“FGFR3 behaves as an oncogene in multiple myeloma [67] and is involved in mitogenesis in myoblasts and hemopoietic cells [68,69].”
Background
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
Goriely, A., Hansen, R. M. S., Taylor, I. B., Olesen, I. A., Jacobsen, G. K., McGowan, S. J., Pfeifer, S. P., McVean, G. A. T., Meyts, E. R.-D., & Wilkie, A. O. M. (2009) · Nature Genetics · doi:10.1038/ng.470 · Cited by 205
Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy
Elenitoba-Johnson, K., Jenson, S. D., Abbott, R. T., Palais, R. A., Bohling, S., Lin, Z.-S., Tripp, S. R., Shami, P., Wang, L.-Y., Coupland, R., et al. (2003) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1137463100 · Cited by 208
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Dispenzieri, A. A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Russell, S. J., Hayman, S. R., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.3.323 · Cited by 222
Self-citation
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern
Hafner, C. M., López‐Knowles, E., Luis, N. M., Toll, A., Baselga, E., Fernandez-Casado, A., Hernandez, S. F., Ribé, A., Mentzel, T., Stoehr, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705218104 · Cited by 210
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q.-L., Chen, C. I., Reece, D., Chun, K., & Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04867.x · Cited by 201
“The major partner genes include cyclin D1(11q13) (Chesi et al, 1996), cyclin D3 (6p21) (Shaughnessy et al, 2001), FGFR3-MMSET (4p16Æ3) (Chesi et al, 1997, 1998a), c-maf (16q23) (Chesi et al, 1998b) and mafB(20q11) (Hanamura et al, 2001).”
BackgroundMethodInfluential
RTK mutations and human syndromes: when good receptors turn bad
Robertson, S. C., Tynan, J. A., & Donoghue, D. J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02077-1 · Cited by 167
Mechanisms of FGFR-mediated carcinogenesis
Ahmad, I., Iwata, T., & Leung, H. Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.004 · Cited by 188
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
Lamont, F., Tomlinson, D., Cooper, P., Shnyder, S., Chester, J., & Knowles, M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606016 · Cited by 191
“3;q32) translocation found in these malignancies results in dysregulated FGFR3 expression in about 15–20% of patients (Chesi et al, 1997, 1998; Keats et al, 2003; Santra et al, 2003).”
Background
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Logié, A., Dunois‐Lardé, C., Rosty, C., Levrel, O., Blanche, M., Ribeiro, A., Gasc, J., Jorcano, J., Werner, S., Sastre-Garau, X., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi127 · Cited by 191
Frequent FGFR3 mutations in urothelial papilloma
van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jöbsis, A. C., & van der Kwast, T. (2002) · The Journal of Pathology · doi:10.1002/path.1202 · Cited by 189
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
Presta, M., Chiodelli, P., Giacomini, A., Rusnati, M., & Ronca, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.013 · Cited by 200
In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models
Lee, S. H., Menezes, D. L. D., Vora, J., Harris, A. L., Ye, H., Nordahl, L., Garrett, E. N., Samara, E. E., Aukerman, S. L., Gelb, A. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2129 · Cited by 174
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
Shaughnessy, J., Tian, E., Sawyer, J., Bumm, K., Landes, R. D., Badros, A., Morris, C. J., Tricot, G., Epstein, J., & Barlogie, B. (2000) · Blood · doi:10.1182/blood.v96.4.1505.h8001505_1505_1511 · Cited by 184
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Tiong, K. H., Mah, L. Y., & Leong, C. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0886-7 · Cited by 181
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
Gutiérrez, N., Castellanos, M., Martín, M., Mateos, M., Hernandez, J., Fernández, M., Carrera, D., Rosiñol, L., Ribera, J.-M., Ojanguren, J. M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404413 · Cited by 181
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.
de Vos, J., Couderc, G., Tarte, K., Jourdan, M., Requirand, G., Delteil, M., Rossi, J., Mechti, N., & Klein, B. (2001) · Blood · doi:10.1182/blood.v98.3.771 · Cited by 177
Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis
Plowright, E. E., Li, Z., Bergsagel, P. L., Chesi, M., Barber, D. L., Branch, D. R., Hawley, R. G., & Stewart, A. K. (2000) · Blood · doi:10.1182/blood.v95.3.992.003k29_992_998 · Cited by 164
Self-citation
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.
Reiter, A., Sohal, J., Kulkarni, S., Chase, A., Macdonald, D., Aguiar, R., Gonçalves, C., Hernández, J., Jennings, B., Goldman, J., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1735.417k11_1735_1742 · Cited by 175
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller, G., Schmidt, W., Ziegler, B., Holzer, S., Müllauer, L., Bilban, M., Zielinski, C., Drach, J., & Zöchbauer-Müller, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2531 · Cited by 174
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Sootome, H., Fujita, H., Ito, K., Ochiiwa, H., Fujioka, Y., Ito, K., Miura, A., Sagara, T., Ito, S., Ohsawa, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2568 · Cited by 165
Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2
Joos, S., Granzow, M., Holtgreve-Grez, H., Siebert, R., Harder, L., Martín-Subero, J., Wolf, J., Adamowicz, M., Barth, T., Lichter, P., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10845 · Cited by 165
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
Trudel, S., Ely, S. A., Farooqi, Y., Affer, M., Robbiani, D. F., Chesi, M., & Bergsagel, P. L. (2004) · Blood · doi:10.1182/blood-2003-10-3650 · Cited by 161
Self-citation
FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).
Guasch, G., Mack, G., Popovici, C., Dastugue, N., Birnbaum, D., Rattner, J., & Pébusque, M. (2000) · Blood · doi:10.1182/blood.v95.5.1788.005k15_1788_1796 · Cited by 162
Characterization of the MM.1 human multiple myeloma (MM) cell lines
Greenstein, S., Krett, N. L., Kurosawa, Y., Ma, C., Chauhan, D., Hideshima, T., Anderson, K. C., & Rosen, S. T. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00023-7 · Cited by 149
LETM1, a novel gene encoding a putative EF-hand Ca(2+)-binding protein, flanks the Wolf-Hirschhorn syndrome (WHS) critical region and is deleted in most WHS patients.
Endele, S., Fuhry, M., Pak, S., Zabel, B., & Winterpacht, A. (1999) · Genomics · doi:10.1006/geno.1999.5881 · Cited by 159
Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12;q12)
Popovici, C., Adélaı̈de, J., Ollendorff, V., Chaffanet, M., Guasch, G., Jacrot, M., Leroux, D., Birnbaum, D., & Pébusque, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5712 · Cited by 146
Multiple myeloma: biology of the disease
Mahindra, A. K., Hideshima, T., & Anderson, K. C. (2010) · Blood Reviews · doi:10.1016/s0268-960x(10)70003-5 · Cited by 157
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
Grand, E., Chase, A., Heath, C., Rahemtulla, A., & Cross, N. (2004) · Leukemia · doi:10.1038/sj.leu.2403347 · Cited by 158
“3;q32) is associated with 10–20p of cases of multiple myeloma (MM) and is believed to dysregulate the expression of two genes, MMSET on the der(4) and FGFR3 on the der(14)”
Background
Identification of genes modulated in multiple myeloma using genetically identical twin samples
Munshi, N. C., Hideshima, T., Carrasco, D. E., Shammas, M. A., Auclair, D., Davies, F. E., Mitsiades, N., Mitsiades, C. S., Kim, R. S., Li, C., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0402 · Cited by 137
Fluorescence in situ hybridization: Uses and limitations
Gozzetti, A., & Beau, M. M. L. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90013-1 · Cited by 187
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155
FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway
Kang, S., Dong, S., Gu, T.-L., Guo, A., Cohen, M. S., Lonial, S., Khoury, H. J., Fabbro, D., Gilliland, D. G., Bergsagel, P. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.003 · Cited by 154
“The translocations usually result in dysregulated expression of several heterogeneous partners including c-myc, cyclin D1 (Chesi et al., 1996), c-maf (Chesi et al., 1998a), and FGFR3 (Chesi et al., 1997).”
BackgroundSelf-citation

Authors: Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L.
Affiliations: National Institutes of Health (US)
Cornell University (US)
Corresponding author: Kuehl, W. Michael
ORCID: Chesi, Marta
Schröck, Evelin
Ried, Thomas
Bergsagel, P. Leif
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1997-07
Volume: 16
Issue: 3
Pages: 260-264
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0797-260
PMC: PMC3901950
OpenAlex: W2054290966
Cited by: 637
References: 0
Citations by year: 2026: 4 · 2025: 3 · 2024: 13 · 2023: 14 · 2022: 11 · 2021: 11 · 2020: 14 · 2019: 16 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 15 · 2014: 23 · 2013: 21 · 2012: 26
FWCI: 17.29
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K01CA074265)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords: multiple myeloma, FGFR3, activating mutations, somatic mutations, myeloma cell lines, thanatophoric dwarfism
MeSH terms: Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Humans, Karyotyping, Molecular Sequence Data, Multiple Myeloma, Mutation, Oncogenes, Protein-Tyrosine Kinases, RNA, Messenger, Translocation, Genetic, Tumor Cells, Cultured, Blotting, Southern, Immunoblotting, Blotting, Northern, DNA Probes, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Receptors, Fibroblast Growth Factor, Receptor, Fibroblast Growth Factor, Type 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks